Hoth Therapeutics Inc (HOTH) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Hoth Therapeutics Inc (HOTH) has a cash flow conversion efficiency ratio of -0.362x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.97 Million) by net assets ($8.20 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Hoth Therapeutics Inc for the company's overall valuation and market capitalisation.
Hoth Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Hoth Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Hoth Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Hoth Therapeutics Inc ranked by their cash flow conversion efficiency. See Hoth Therapeutics Inc cash debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Pulsenmore Ltd. Ordinary Shares
NASDAQ:PLSM
|
-0.304x |
|
Immo Mcc NV
BR:MCC
|
N/A |
|
Americas Car-Mart Inc
NASDAQ:CRMT
|
0.213x |
|
Pimpinan Eshan Bhd
KLSE:5622
|
-0.015x |
|
Klaria Pharma Holding AB
ST:KLAR
|
0.004x |
|
HPMT Holdings Bhd
KLSE:5291
|
-0.045x |
|
Barnwell Industries Inc
NYSE MKT:BRN
|
-0.216x |
|
Floyd Public Company Limited
BK:FLOYD
|
0.048x |
Annual Cash Flow Conversion Efficiency for Hoth Therapeutics Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Hoth Therapeutics Inc from 2017 to 2025. View Hoth Therapeutics Inc stock price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $6.15 Million | $-9.80 Million | -1.594x | -57.12% |
| 2024-12-31 | $6.88 Million | $-6.98 Million | -1.014x | -14.55% |
| 2023-12-31 | $9.54 Million | $-8.45 Million | -0.886x | +51.22% |
| 2022-12-31 | $5.12 Million | $-9.30 Million | -1.815x | -48.39% |
| 2021-12-31 | $9.88 Million | $-12.09 Million | -1.223x | +7.33% |
| 2020-12-31 | $4.65 Million | $-6.13 Million | -1.320x | +36.06% |
| 2019-12-31 | $2.40 Million | $-4.95 Million | -2.065x | +84.78% |
| 2018-12-31 | $154.97K | $-2.10 Million | -13.568x | -3354.39% |
| 2017-12-31 | $1.18 Million | $-465.24K | -0.393x | -- |
About Hoth Therapeutics Inc
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs in the United States. It develops HT-001, a topical formulation in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to … Read more